The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes

NCT01795248 on ClinicalTrials.gov · last registry update 2020-11-04

Finished September 2019, after enrolling 105 people. Primary outcome, as filed: Change in glucose tolerance. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Tina Vilsboll
Sponsor type: Other
Enrollment: 105
Started: 2012-07
Primary completion: 2019-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in glucose tolerance

Conditions studied

Gestational Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.